Business
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
VANCOUVER, British Columbia, April 01, 2026--AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
About this update from Abcellera Biologics Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":339,"url":"https://media.zenfs.com/en/business-wire.com/b9d1e2a465c2882a83cef614aa9c5f96"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I4LKft2G0NbkLLXXoHwPTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY3OA--/https://media.zenfs.com/en/business-wire.com/b9d1e2a465c2882a83cef614aa9c5f96","width":480,"height":339}},"lazy":false},{"type":"text","content":"VANCOUVER, British Columbia, April 01, 2026--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) will announce its first quarter 2026 financial results on Monday, May 11, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.","length":268,"tagName":"p"},{"type":"text","content":"A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call.","length":221,"tagName":"p"},{"type":"text","content":"About AbCellera Biologics Inc.","length":30,"tagName":"p"},{"type":"text","content":"AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For more information, please visit www.abcellera.com.","length":277,"tagName":"p"},{"type":"text","content":"View source version on businesswire.com: https://www.businesswire.com/news/home/20260401189819/en/","length":98,"tagName":"p"},{"type":"text","content":"Contacts","length":8,"tagName":"p"},{"type":"text","content":"Inquiries Media: Tiffany Chiu; [email protected], +1(236)521-6774Partnering: Murray McCutcheon, Ph.D.; [email protected], +1(604)559-9005Investor Relations: Peter Ahn; [email protected], +1(778)729-9116","length":213,"tagName":"p"}]